FNCHQ.US Finch Therapeutics Group, Inc.
- Market cap
- USD 16.6M
- P/E
- -
- P/B
- 1.14x
- ROE
- -152.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is FNCHQ.US undervalued?
Graham numberThe Graham number of Finch Therapeutics Group, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Finch Therapeutics Group, Inc. fundamental analysis
No fundamental analysis for Finch Therapeutics Group, Inc. yet.
Finch Therapeutics Group, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease…
Full company profileFinch Therapeutics Group, Inc. financial statements
Finch Therapeutics Group, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 10.2M | 7.72M | 18.5M | 861K | 107K | - |
| Gross Profit | 9.84M | -25.4M | -38.7M | -4.65M | -1.41M | -174K |
| Operating Income | -21.1M | -39.4M | -60.0M | -95.1M | -34.0M | -18.9M |
| EBITDA | -20.7M | -38.6M | -57.7M | -82.7M | -32.5M | -13.7M |
| Net Income | -20.8M | -39.2M | -58.2M | -115M | -74.8M | -13.9M |
| EPS | -13 | -24 | -37 | -72 | -47 | -8.64 |
| Balance Sheet | ||||||
| Total Assets | 104M | 165M | 225M | 163M | 55.4M | 49.8M |
| Total Liabilities | 163M | 261M | 23.1M | 67.2M | 32.5M | 40.7M |
| Shareholders' Equity | -59.5M | -95.7M | 202M | 95.7M | 22.9M | 9.08M |
| Cash & Short-term Investments | 42.2M | 99.7M | 133M | 71.0M | 25.1M | 10.3M |
| Total Debt | 143M | 1.81M | 10.9M | 52.3M | 30.1M | 27.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -17.3M | -31.3M | -67.1M | -74.9M | -31.5M | - |
| Capital Expenditure | 1.01M | 2.63M | 16.0M | 2.18M | 0.00 | - |
| Free Cash Flow | -18.3M | -34.0M | -83.1M | -77.0M | -31.5M | - |
| Ratios | ||||||
| ROE | - | - | -28.8% | -119.8% | -326.6% | -152.8% |
| ROA | -20.0% | -23.7% | -25.8% | -70.4% | -135.0% | -27.9% |
| Net Profit Margin | -204.4% | -508.5% | -313.8% | -13,315.4% | -69,863.6% | - |
| Debt to Equity | - | - | 0.05x | 0.55x | 1.32x | 3.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Finch Therapeutics Group, Inc. dividends
Finch Therapeutics Group, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:30 on Jun 12, 2023.
Who owns Finch Therapeutics Group, Inc.
Ownership data of Finch Therapeutics Group, Inc. is not available yet.
Finch Therapeutics Group, Inc. company profile
- Company name
- Finch Therapeutics Group, Inc.
- Ticker
- FNCHQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 75 State Street, Boston, MA, United States, 02109
- Phone
- 617 229 6499
- Website
- finchtherapeutics.com
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on September 3, 2026.
Finch Therapeutics Group, Inc. management
2- Mr. Matthew P. Blischak J.D.President, Secretary & CEO · born 1963
- Mr. James S. Sigler MBAExecutive Vice President of CMC · born 1961